Company intelligence / Profile preview

Marchar Laboratories

El Paso, Texas, United States

Ownership: Private
Development stage: Other

Overview

Marchar Laboratories is a pre-clinical stage biotechnology company focused on developing next-generation small molecule therapeutics for oncology, specifically targeting hormone-driven cancers. The company's lead research efforts center on novel androgen receptor (AR) antagonists designed to overcome resistance mechanisms in advanced prostate cancer, including the AR-V7 splice variant. By utilizing a unique chemical scaffold, Marchar Laboratories aims to provide more effective treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed standard-of-care therapies like enzalutamide or abiraterone.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Marchar Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marchar Laboratories.

Explore the full profile